Companion Animals

Companion Cat IBD Final 2026

A final 2026 overview of feline IBD management advances and priorities for continued improvement in welfare outcomes.

Key Facts

IBD remains a leading cause of chronic morbidity in cats over 5 years old
Microbiome testing is becoming accessible in specialist practice enabling targeted treatment
FMT clinical trials are ongoing with early positive results for refractory cases
Dietary management advances including novel protein sources improve palatability and compliance
Biomarker monitoring panels are reducing invasive biopsy requirements for disease monitoring

Welfare Considerations

Feline IBD management in 2026 is better than it has ever been, with microbiome science and new therapeutic approaches expanding options beyond conventional immunosuppression. The welfare trajectory is positive - more precise diagnosis, more targeted treatment, and better monitoring are collectively reducing the burden of chronic disease. The challenge is extending these advances from specialist to general practice so all IBD cats benefit from current best practice.

What You Can Do

Seek specialist gastroenterology referral for cats with IBD not responding to initial treatment
Follow feline IBD research for new therapeutic approaches as evidence develops
Advocate for investment in feline gut health research as a welfare priority